Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Total Liabilities
Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has total liabilities worth CN¥59.30 Billion CNY (≈ $8.68 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Shanghai Fosun Pharmaceutical Group Co L to track the company's year-over-year net asset growth rate.
Shanghai Fosun Pharmaceutical Group Co Ltd - Total Liabilities Trend (1995–2025)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Shanghai Fosun Pharmaceutical Group Co L (600196) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Fosun Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Gap, Inc.
NYSE:GAP
|
USA | $8.48 Billion |
|
Shanghai Zhangjiang Hi-Tech Park Development Co Ltd
SHG:600895
|
China | CN¥43.41 Billion |
|
Aurubis AG
XETRA:NDA
|
Germany | €4.49 Billion |
|
Suzhou Everbright Photonics Co. Ltd. A
SHG:688048
|
China | CN¥320.36 Million |
|
Torrent Power Limited
NSE:TORNTPOWER
|
India | Rs208.90 Billion |
|
Pegatron Corp
TW:4938
|
Taiwan | NT$385.83 Billion |
|
Valley National Bancorp
NASDAQ:VLY
|
USA | $56.47 Billion |
|
Beijer Ref AB (publ)
ST:BEIJ-B
|
Sweden | Skr23.89 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Shanghai Fosun Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Fosun Pharmaceutical Group Co L (600196) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Fosun Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Fosun Pharmaceutical Group Co Ltd (1995–2025)
The table below shows the annual total liabilities of Shanghai Fosun Pharmaceutical Group Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥57.97 Billion ≈ $8.48 Billion |
+0.78% |
| 2024-12-31 | CN¥57.53 Billion ≈ $8.42 Billion |
+1.18% |
| 2023-12-31 | CN¥56.85 Billion ≈ $8.32 Billion |
+7.16% |
| 2022-12-31 | CN¥53.05 Billion ≈ $7.76 Billion |
+18.11% |
| 2021-12-31 | CN¥44.92 Billion ≈ $6.57 Billion |
+19.14% |
| 2020-12-31 | CN¥37.70 Billion ≈ $5.52 Billion |
+2.13% |
| 2019-12-31 | CN¥36.92 Billion ≈ $5.40 Billion |
-0.12% |
| 2018-12-31 | CN¥36.96 Billion ≈ $5.41 Billion |
+14.67% |
| 2017-12-31 | CN¥32.23 Billion ≈ $4.72 Billion |
+74.05% |
| 2016-12-31 | CN¥18.52 Billion ≈ $2.71 Billion |
+5.62% |
| 2015-12-31 | CN¥17.53 Billion ≈ $2.57 Billion |
+8.00% |
| 2014-12-31 | CN¥16.23 Billion ≈ $2.38 Billion |
+37.45% |
| 2013-12-31 | CN¥11.81 Billion ≈ $1.73 Billion |
+15.76% |
| 2012-12-31 | CN¥10.20 Billion ≈ $1.49 Billion |
-6.57% |
| 2011-12-31 | CN¥10.92 Billion ≈ $1.60 Billion |
+47.03% |
| 2010-12-31 | CN¥7.43 Billion ≈ $1.09 Billion |
+62.33% |
| 2009-12-31 | CN¥4.58 Billion ≈ $669.48 Million |
+47.92% |
| 2008-12-31 | CN¥3.09 Billion ≈ $452.60 Million |
-0.82% |
| 2007-12-31 | CN¥3.12 Billion ≈ $456.35 Million |
+4.46% |
| 2006-12-31 | CN¥2.99 Billion ≈ $436.85 Million |
+6.86% |
| 2005-12-31 | CN¥2.79 Billion ≈ $408.80 Million |
+18.54% |
| 2004-12-31 | CN¥2.36 Billion ≈ $344.86 Million |
+7.03% |
| 2003-12-31 | CN¥2.20 Billion ≈ $322.21 Million |
+50.18% |
| 2002-12-31 | CN¥1.47 Billion ≈ $214.55 Million |
+65.73% |
| 2001-12-31 | CN¥884.68 Million ≈ $129.46 Million |
+150.90% |
| 2000-12-31 | CN¥352.61 Million ≈ $51.60 Million |
+75.30% |
| 1999-12-31 | CN¥201.15 Million ≈ $29.43 Million |
+72.86% |
| 1998-12-31 | CN¥116.36 Million ≈ $17.03 Million |
-24.66% |
| 1997-12-31 | CN¥154.46 Million ≈ $22.60 Million |
+94.74% |
| 1996-12-31 | CN¥79.32 Million ≈ $11.61 Million |
-2.20% |
| 1995-12-31 | CN¥81.10 Million ≈ $11.87 Million |
-- |
About Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more